http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022053641-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f4f8755c361b70eb6af66fd6a114e590
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e249b90fe5734719be6d28faa3ada2eb
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-06
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P39-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-501
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-06
filingDate 2021-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_090845f0a77e4166fb5104d7d7823fff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_503c31b3794a467acf4831b32f70394a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_434ef9953243ec00108ea02a26889169
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a4677f34bc161bd3173ccc28e32ba59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e4c57d5bf2c6d1495df4397d195dffe0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b4eaaae25edbea5dee92eaec7c46937e
publicationDate 2022-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2022053641-A1
titleOfInvention Diazinoximes scaffolds
abstract The present invention relates to a compound of formulas (II) to (V). It also relates to a pharmaceutical composition comprising at least one compound of formulas (II) to (V) and at least one pharmaceutically acceptable support. Finally, it relates to the use of such a compound as a medicine, preferably in the treatment of a nervous and/or respiratory failure due to intoxication with at least one organophosphorous nerve agent by reactivation of hAChE; in the treatment of neurological diseases such as Alzheimer's disease; and/or in the treatment of cancer.
priorityDate 2020-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3696170-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2873663-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID162753378
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID471475935
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466046585
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465022300
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465022301
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID162753365
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID471638135
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID136045249
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID471640192
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID471654420
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465050888
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID162753385
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465614068
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465340239
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467378717
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID162753372
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466250993
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466383536
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID162753343
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID162753346
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID464964332
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID162753347
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466925118
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID468296769

Total number of triples: 48.